The largest database of trusted experimental protocols
> Chemicals & Drugs > Indicator > Gadolinium

Gadolinium

Gadolinium is a rare-earth metal with the atomic number 64.
It has important applications in medical imaging, particularly as a contrast agent in magnetic resonance imaging (MRI) scans.
Gadolinium-based contrast agents enhance the visualization of tissues and organs, allowing for more accurate diagnosis and monitoring of various health conditions.
Researhcers are continuously exploring new ways to optimize the use of gadolinium in clinical settings, focusing on factors such as safety, efficacy, and reproducibility.
The PubCompare.ai platform can help streamline this process by enabling researchers to seamlessly compare data from literature, pre-prints, and patents, ultimately improving the quality and impact of gadolinium-related studies.

Most cited protocols related to «Gadolinium»

Though the vast majority of recent MRI studies of white matter have focused on diffusion, MT or relaxometry, there are other techniques that may provide complementary information. One of the oldest methods is MR spectroscopy, which may be used to characterize specific metabolites in the tissue including NAA (N-acetylaspartate), creatine, choline and neurotransmitters like GABA and glutamine/glutamate. Each of these metabolites reflects different physiological processes and have unique spectral signatures. Of significant interest in white matter is NAA, which is a marker of the presence, density and health of neurons including the axonal processes. In fact, NAA may be one of the most specific markers of healthy axons and, as such, it is surprising that it is not used more widely for the investigation of white matter in the brain. This may be due in part to the fact that MR spectroscopy is extremely sensitive to the homogeneity of the magnetic field, which makes it challenging to apply in areas near air or bone interfaces. The concentrations of the metabolites are also in the micromolar range (compare with multiple molar for water), thus, large voxels must be used and the acquisition speed is slow. Therefore, MR spectroscopy studies are often limited by poor coverage, poor resolution, and long scan times.
The recent push towards ever higher magnetic fields makes quantitative MRI methods more challenging. Imaging distortions in DTI studies increase proportional to the field strength. The RF power deposition (SAR – specific absorption rate) increases quadratically with the magnetic field strength, which limits the application of MT pulses and can also limit the flip angles used in steady state imaging. However, susceptibility weighted imaging is one method that greatly benefits from higher magnetic field strengths. Recent studies have observed interesting contrast in white matter tracts as a function of orientation and degree of myelination (Liu et al., 2011 ). Stunning images of white matter tracts have recently been obtained in ex vivo brain specimens (Sati et al., 2011 ). Techniques for characterizing white matter in the human brain are only beginning to be developed.
Other white matter cellular components are the glia, which include oligodendrocytes, astrocytes, and microglia. In general, there are no specific markers of changes in either oligodendrocytes or astrocytes. Recent evidence suggests that hypointense white matter lesions on T1w imaging may indicate reactive astrocytes (Sibson et al., 2008 (link)). Increases in microglia often accompany inflammation, which can be detected using contrast agents, either gadolinium or superparamagnetic iron oxide (SPIO) particles. Recent studies have suggested that SPIO particles are preferentially taken up by macrophages in inflammatory regions. The impact of these contrast agents on other quantitative MRI measures have not (Oweida et al., 2004 (link)) been widely studied, thus multimodal imaging studies must be designed carefully.
Publication 2011
Astrocytes Axon Bones Brain Cellular Structures Choline Contrast Media Creatine Diffusion ferric oxide Gadolinium gamma Aminobutyric Acid Glutamate Glutamine Homo sapiens Inflammation Macrophage Magnetic Fields Magnetic Resonance Spectroscopy Microglia Molar Myelin Sheath N-acetylaspartate Neuroglia Neurons Neurotransmitters Oligodendroglia Physiological Processes Pulses Radionuclide Imaging Susceptibility, Disease Tissues White Matter
Experiments were performed on a Philips 3T MRI scanner (Philips Medical Systems, Best, The Netherlands) using a body coil for RF transmission and a 6-channel phased-array coil for reception. A continuous-wave (CW) RF saturation scheme was used of power 4 µT and duration 500 ms (which currently is the longest allowed for our body coil). A single-slice turbo spin-echo (TSE) imaging readout with a SENSE (sensitivity encoding) factor of 2 and a TSE factor (number of refocusing pulses) of 32 was used (which therefore equals a single-shot acquisition of 64 phase-encoding steps). Other imaging parameters were: TR/TE = 3000/30ms, matrix = 128×64 (zero-filled to 256×256), FOV = 200×200 mm2, and slice thickness = 5 mm. Higher-order (up to second order) shimming was employed in this study. High-SNR APT-weighted (APTw) images were acquired using six frequency offsets (namely, ±3, ±3.5, ±4 ppm) and 8 signal averages. In an extra scan, a z-spectrum was acquired (33 offsets from 8 to −8 ppm with intervals of 0.5 ppm, one average). For both scans, one unsaturated image (without RF saturation, same TR) was acquired for normalization. The scan times were 2 min 48 sec and 1 min 42 sec, respectively, totaling 4 min 30 sec for these two scans. In addition, higher-order shimming was incorporated into the prescan of the high-SNR APT scan and performed by the scanner automatically, which took about 10 sec extra. Because four extra offsets around ±3.5 ppm were acquired in the high SNR scan, it is possible to correct for the artifacts caused by B0 inhomogeneity (see below).
Standard T2-weighted (T2w), T1-weighted (T1w), fluid attenuated inversion recovery (FLAIR), and gadolinium-enhanced T1w (Gd-T1w) images were acquired for reference. The parameters used were: T2w (TSE factor = 8, TR/TE = 4000/80 ms, 60 slices, 2.2 mm thick), T1w and Gd-T1w (three-dimensional (3D) magnetization-prepared-rapid-gradient-echo (MPRAGE), TR/TE/TI = 3000/3.7/843 ms, flip angle = 8°, 120 slices, 1.1 mm isotropic voxels), and FLAIR (TSE factor = 19, TR/TE/TI = 11000/120/2800 ms, 60 slices, 2.2 mm thick). Conventional MT imaging was incorporated into the high-SNR APT scan (with the same parameters, except offset = 2000 Hz) and acquired simultaneously to share its non-saturated (S0) image.
Publication 2008
ECHO protocol Gadolinium Human Body Hypersensitivity Inversion, Chromosome Pulses Radionuclide Imaging Transmission, Communicable Disease

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Acceleration ECHO protocol Epistropheus factor A Gadolinium Heart Inversion, Chromosome Microtubule-Associated Proteins Myocardium Patients Pentetic Acid Physical Examination Physicians Reading Frames
The proposed sequence and in-line flow mapping was performed at stress and rest on 29 healthy normal volunteers (11 men and 18 women, mean age 25.4 ± 5.7 years) at the Karolinska University Hospital, Stockholm, Sweden. Studies were approved by the local Ethics Committee. Anonymized data was analyzed at NIH with approval by the NIH Office of Human Subjects Research OHSR (Exemption #13156). All imaging was performed at 1.5 T (Magnetom AERA, Siemens, software version VE11A). Gadolinium (Gd) contrast agent (Gadobutrol) was administered as a bolus with 0.5 dose (0.05 mmol/kg) at 4 mL/s with 20 mL saline flush. One cannula was used for administration of adenosine and another cannula for the administration of contrast agent. Adenosine was administered by continuous infusion for approximately 8 min at a dose of 140 μg/kg/min to allow for additional research scans at stress just prior to contrast administration. The SSFP protocol was used in this study with fat saturation enabled.
In-vivo studies were performed to test the sequence and LUT conversion of signal intensities. Peak [Gd] was measured for the AIF blood pool signal and myocardium, as well as peak SNR in the myocardium from SNR scaled signal intensities. Blood pool T2* values at peak [Gd] were measured as well as the influence of T2* correction on estimates of myocardial blood flow. Duration of the bolus first pass was measured automatically from the AIF signal from the foot of the curve on the upslope of the AIF to the foot of the downslope. The improvement in linearity of the AIF after conversion to gadolinium concentration was measured by the ratio of the AIF peak to valley following the peak, for the raw signal intensities and for the LUT corrected [Gd].
Full text: Click here
Publication 2017
Adenosine BLOOD Blood Circulation Cannula Flushing Foot gadobutrol Gadolinium Healthy Volunteers Myocardium Radionuclide Imaging Regional Ethics Committees Saline Solution Woman
All routine CMR analysis was performed using commercially available software (ViewForum, Extended Workspace, Philips Healthcare, The Netherlands). Endocardial LV borders were manually traced at end-diastole and end-systole. The papillary muscles were included as part of the LV cavity volume. LV end-diastolic (EDV) and end-systolic (ESV) volumes were determined using Simpson’s rule. Ejection fraction (EF) was computed as EDV-ESV/EDV. All volumetric indices were normalized to body surface area (BSA).
For each subject T1, relaxation values were measured separately by two independent observers. Chosen regions of interest (ROIs) were automatically propagated across all eleven images in the MOLLI sequence with a prior image- co-registration step for motion-correction [3 (link)]. Care was particularly taken to avoid ‘contamination’ with signal from the blood pool.
Two main approaches to place myocardial ROIs within the mid-SAX slice were examined: Septal and SAX myocardial ROI (Figure 1). An additional lateral myocardial ROI was also examined for regional differences in T1 values. In addition to the T1 values of native myocardium and blood pool, we calculated lambda (λ), a marker of interstitial contrast agent accumulation according to the formula λ = [Δ R1myocardium]/[Δ R1bloodpool] pre and post gadolinium contrast where R1 = 1/T1 [11 (link),12 (link)].
Full text: Click here
Publication 2013
BLOOD Body Surface Area Dental Caries Diastole Endocardium Gadolinium Myocardium Papillary Muscles Systole

Most recents protocols related to «Gadolinium»

Example 17

50 μmol (Gd3+) of AGuIX® were redispersed in 125 μl of ultrapure water in order to obtain a solution at 400 mM [Gd3+]. 2.8 mg of cisplatin are placed in a 2.5 ml flask. 1.1 ml of ultrapure water are added to the flask, which is stirred. Since cisplatin is not very soluble at ambient temperature, it is necessary to heat to 40° C. until it is completely dissolved. A solution containing 2.5 g/l of cisplatin is then obtained, and is protected from the light with aluminium. 229 μl of this solution are then added to the solution of AGuIX®, as are 146 μl of ultrapure water. The flask is stirred for 30 minutes in the dark. A solution containing 100 mM of gadolinium and 1160 mg/l of cisplatin is thus obtained.

This solution is placed in a 3 kDa Vivaspin®, and a tangential filtration cycle is carried out so as to obtain a supernatant of 160 μl. The subnatant is analysed by UV-visible analysis. The cisplatin is detectable by UV/VIS absorption at a wavelength of 706 nm after reaction with ODPA. For the reaction with cisplatin, a solution of ODPA at 1.4 mg/ml and a phosphate buffer (pH 6.8) are prepared. The subnatant is diluted 5-fold. 140 μl of this solution are added to 200 μl of buffer and 100 μl of ODPA. The resulting solution is heated at 100° C. for 15 min.

Once the reaction is finished and the temperature has returned to ambient temperature, 560 μl of DMF are added. The final solution is filtered and then analysed by UV-visible analysis.

Full text: Click here
Patent 2024
AGuIX Aluminum Buffers Cisplatin Filtration Gadolinium Light Phosphates

Example 9

50 μmol (Gd3+) of the AGuIX® nanoparticles were redispersed in 125 μl of ultrapure water in order to obtain a solution at 400 mM ([Gd3+]). 14.94 mg of tyr3-octreotate (TATE) peptide are placed in a 2.5 ml flask. 498 μl of ultrapure water are added to the flask, which is stirred until the peptide has completely dissolved. A solution containing 30 g/l of peptide is then obtained. 193 μl of this solution are then added to the solution of AGuIX®, as are 182 μl of ultrapure water. The flask is stirred for 30 minutes. A solution containing 100 mM of gadolinium and 11.60 g/l of peptide is thus obtained.

This solution is placed in a 3 kDa Vivaspin®, and a tangential filtration cycle is carried out so as to obtain a supernatant of 200 μl. The subnatant is analysed by UV-visible analysis and fluorometry after 20-fold dilution.

Full text: Click here
Patent 2024
AGuIX Filtration Fluorometry Gadolinium peptide L Peptides Technique, Dilution

Example 8

50 μmol (Gd3+) of the AGuIX® nanoparticles were redispersed in 125 μl of ultrapure water in order to obtain a solution at 400 mM ([Gd3+]). 6.1 mg of tyr3-octreotate (TATE) peptide are placed in a 2.5 ml flask. 203.3 μl of ultrapure water are added to the flask, which is stirred until the peptide has completely dissolved. A solution containing 30 g/l of peptide is then obtained. 97 μl of this solution are then added to the solution of AGuIX®, as are 279 μl of ultrapure water. The flask is stirred for 30 minutes. A solution containing 100 mM of gadolinium and 5.80 g/l of peptide is thus obtained.

This solution is placed in a 3 kDa Vivaspin®, and a tangential filtration cycle is carried out so as to obtain a supernatant of 320 μl. The subnatant is analysed by UV-visible analysis (20-fold dilution) and fluorometry (40-fold dilution).

Full text: Click here
Patent 2024
AGuIX Filtration Fluorometry Gadolinium peptide L Peptides Technique, Dilution

Example 3

50 μmol (Gd3+) of AGuIX® nanoparticles were redispersed in 125 μl of ultrapure water in order to obtain a solution at 400 mM ([Gd3+]). 2.85 mg of doxorubicin are placed in a 2.5 ml flask. 1.1 ml of ultrapure water are added to the flask, which is stirred until the doxorubicin has completely dissolved. A solution at 2.6 g/l of doxorubicin is then obtained, and is protected from the light with aluminium. 327 μl of this solution are then added to the solution of AGuIX®, as are 48 μl of ultrapure water. The flask is stirred for 30 minutes in the dark. A solution containing 100 mM of gadolinium and 170 mg/l of doxorubicin is thus obtained.

This solution is placed in a 3 kDa Vivaspin®, and a tangential filtration cycle is carried out in order to obtain a supernatant of 200 μl. The subnatant is analysed by UV-visible analysis. The supernatant is diluted 50-fold and is analysed by UV-visible analysis.

Example 4

A solution of doxorubicin at 170 mg/l is prepared according to the procedure described in Example 3, the solution of AGuIX® being replaced with ultrapure water.

Full text: Click here
Patent 2024
AGuIX Aluminum Doxorubicin Filtration Gadolinium Light Suby's G solution
Not available on PMC !

Example 11

50 μmol (Gd3+) of the AGuIX® nanoparticles were redispersed in 250 μl of ultrapure water in order to obtain a solution at 200 mM ([Gd3+]). 0.6 mg of tyr3-octreotate (TATE) peptide are placed in a 2.5 ml flask. 20 μl of ultrapure water are added to the flask, which is stirred until the peptide has completely dissolved. A solution containing 30 g/l of peptide is then obtained. 20 μl of this solution are then added to the solution of AGuIX®, as are 230 μl of ultrapure water. The flask is stirred for 30 minutes. A solution containing 100 mM of gadolinium and 1.20 g/l of peptide is thus obtained.

This solution is placed in a 3 kDa Vivaspin®, and a tangential filtration cycle is carried out so as to obtain a supernatant of 320 μl. The subnatant is analysed by UV-visible analysis (20-fold dilution) or fluorometry (40-fold dilution).

Full text: Click here
Patent 2024
AGuIX Filtration Fluorometry Gadolinium peptide L Peptides Technique, Dilution

Top products related to «Gadolinium»

Sourced in Germany, United States, Japan, China, United Kingdom, Jersey, Canada, Ireland
Magnevist is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) procedures. It is designed to enhance the visualization of internal body structures and improve the diagnostic capabilities of MRI scans.
Sourced in Germany, United States, Japan, Canada, Switzerland, United Kingdom, France, Spain
Gadovist is a contrast agent used in magnetic resonance imaging (MRI) procedures. It contains the active ingredient gadobutrol, which enhances the visibility of certain structures within the body during the MRI scan.
Sourced in France, Germany, United States, United Kingdom, Italy
Dotarem is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) procedures. It is designed to enhance the visualization of internal body structures during MRI scans.
Sourced in Germany, United States, France
The Magnetom Avanto is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality imaging for a variety of clinical applications. The Magnetom Avanto utilizes a strong magnetic field and radio waves to generate detailed images of the body's internal structures.
Sourced in Netherlands, Germany, United States, Switzerland, Japan
The Philips Ingenia is a magnetic resonance imaging (MRI) system designed for diagnostic imaging. It provides high-quality images of the body's internal structures to aid in the detection and diagnosis of various medical conditions.
Sourced in Germany, United States
The MAGNETOM Skyra is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality imaging for various medical applications. The MAGNETOM Skyra utilizes advanced technology to generate detailed images of the body's internal structures without the use of ionizing radiation.
Sourced in Germany, United States, United Kingdom
The Magnetom Aera is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality, diagnostic-grade imaging data. The Magnetom Aera utilizes a powerful superconducting magnet and advanced imaging technologies to capture detailed images of the human body's internal structures and functions.
Sourced in Italy, Germany, United States, China
MultiHance is a contrast agent used in magnetic resonance imaging (MRI) procedures. It is a paramagnetic agent that enhances the visualization of internal body structures during the MRI scan. The core function of MultiHance is to improve the contrast between different tissues, allowing for better detection and evaluation of potential abnormalities.
Sourced in Netherlands, Germany, United States, United Kingdom, Japan
The Philips Achieva is a versatile laboratory equipment designed for a range of analytical and research applications. It offers advanced capabilities for tasks such as sample preparation, separation, and detection. The Achieva is engineered to provide reliable and consistent performance, making it a valuable tool for various scientific disciplines.
Sourced in Germany, United States, Japan, United Kingdom
The Magnetom Verio is a magnetic resonance imaging (MRI) system produced by Siemens. It is designed to acquire high-quality images of the human body. The core function of the Magnetom Verio is to generate a strong magnetic field and radio waves, which interact with the hydrogen protons in the body to produce detailed images of internal structures and organs.

More about "Gadolinium"

Gadolinium (Gd) is a rare-earth metal with the atomic number 64, known for its invaluable applications in medical imaging, particularly as a contrast agent in magnetic resonance imaging (MRI) scans.
Gadolinium-based contrast agents, such as Magnevist, Gadovist, Dotarem, and MultiHance, play a crucial role in enhancing the visualization of tissues and organs, allowing for more accurate diagnosis and monitoring of various health conditions.
Researchers are continuously exploring new ways to optimize the use of gadolinium in clinical settings, focusing on factors such as safety, efficacy, and reproducibility.
The PubCompare.ai platform can help streamline this process by enabling researchers to seamlessly compare data from literature, pre-prints, and patents, ultimately improving the quality and impact of gadolinium-related studies.
Gadolinium-enhanced MRI scans, performed on imaging systems like the Magnetom Avanto, Ingenia, MAGNETOM Skyra, Magnetom Aera, and Achieva, have become an essential tool in the medical field, providing healthcare professionals with valuable insights into the body's internal structures and functions.
By enhancing the contrast between different tissues, gadolinium-based agents help clinicians identify and monitor a wide range of conditions, from cancers and organ diseases to neurological disorders and musculoskeletal injuries.
Through the power of AI-driven comparisons, the PubCompare.ai platform empowers researchers to discover the best protocols and products for their gadolinium-related studies, ultimately elevating the quality and impact of their work.
By seamlessly integrating data from various sources, including literature, pre-prints, and patents, researchers can gain a more comprehensive understanding of the latest advancements and best practices in the field, leading to improved reproducibility and accuracy in their findings.